🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhongshan
Clinical trial register · China

Clinical Trials in Zhongshan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University17 Zhongshan People's Hospital, Guangdong, China6 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4 Ming-Yuan Chen3 Nanfang Hospital, Southern Medical University2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhongshan

57 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy Analysis of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Therapy in the Treatment of Chronic Subjective Tinnitus
NCT07794462Chronic Subjective Tinnitus
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
444
Guangzhou, Huizhou, Jieyang, Zhongshan, Zhuhai, Shanghai
2026-10-01
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-30
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis
NCT07784491Allergic Rhinitis
Zhongshan Torch Development Zone People's Hospital
Not applicable
150
Zhongshan
2026-08-31
Recruiting
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
NCT07661771Non-metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Not yet open
Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye
NCT07679685Dry Eye
Beijing Tongren Hospital
Phase 4
159
Beijing, Guangzhou, Shanghai, Xi'an, Zhongshan
2026-06-30
Not yet open
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
NCT07544160Inflammatory Bowel Diseases (IBD)
iCell Gene Therapeutics
Phase 1/2
18
Zhongshan
2026-04-07
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841Nasopharyngeal Carcinoma (NPC)
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss
NCT07505667Sudden Hearing Loss, Sensorineural Hearing Loss
Guangdong Provincial People's Hospital
Not applicable
128
Guangzhou, Shenzhen, Zhongshan, Liuzhou, Ganzhou
2025-11-15
By invitation
Prospective Real-World Study of Multimodal AI
NCT07269236Pancancer
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Zhongshan
2025-10-01
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
NCT06896708Chronic Coronary Syndrome
Liu yong
Not applicable
766
Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian
2025-08-12
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
NCT07070479Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 2
208
Guangzhou, Zhongshan, Zhuhai, Changsha
2025-06-24
Recruiting
PIMS vs PGT-A in Infertile PCOS Patients
NCT06887881PGT-A, PCOS, PIMS
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
766
Zhongshan
2025-06-12
Recruiting
Crisugabalin for Radiotherapy-Related Neuropathic Pain
NCT06766916Neuropathic Pain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
Recruiting
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
NCT07348302Rhinitis, Rhinoconjunctivitis
Inmunotek S.L.
Phase 3
736
Beijing, Guangzhou, Zhongshan, Xiangya, Changzhou, Qingdao, Shanghai, Tongji
2025-04-02
Recruiting
Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
NCT07010198Hepatocellular Cancer (HCC)
Zhongshan People's Hospital, Guangdong, China
Observational
4,500
Zhongshan
2025-03-01
Active, closed
A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head
NCT07471880Osteonecrosis, Osteonecrosis of the Femoral Head
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Phase 2
161
Zhongshan
2024-12-24
Recruiting
WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Quality in China
NCT06702410Neurodevelopmental Disorders
Sun Yat-sen University
Not applicable
375
Zhongshan
2024-11-20
Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282Systemic Lupus Erythematosus (SLE)
AstraZeneca
Observational
200
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
2024-10-22
Recruiting
Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion
NCT06455644Atrial Fibrillation, Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases
First Affiliated Hospital of Shantou University Medical College
Not applicable
238
Foshan, Meizhou, Shantou, Zhongshan
2024-07
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Not yet open
Enhanced External Counter Pulsation on Afterload Mismatch Rate in Post-TEER (PAMPER)
NCT06227286Mitral Regurgitation
Sun Yat-sen University
Not applicable
176
Guangzhou, Jieyang, Shantou, Zhongshan
2024-03-01
Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156Advanced Melanoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Recruiting
Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
NCT05990946Lung Neoplasms, Non-Small Cell Lung Cancer, Postoperative Complications, Patient Reported Outcome Measures, Telerehabilitation
Zhongshan People's Hospital, Guangdong, China
Not applicable
736
Zhongshan
2023-12-01
Recruiting
Xerostomia-optimised IMRT Versus Standard IMRT in NPC
NCT06282497Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy
Zhongshan People's Hospital, Guangdong, China
Not applicable
524
Zhongshan
2023-10-23
Active, closed
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
NCT05979961Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Recruiting
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
NCT05994170Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy
Zhongshan People's Hospital, Guangdong, China
Not applicable
454
Zhongshan
2023-08-04
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Active, closed
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Recruiting
REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry
NCT05728775Anesthesia, Surgery-Complications
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Recruiting
Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
NCT05884983Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
Observational
12,000
Zhongshan
2023-02-01
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)
NCT05582265Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
537
Guanzhou, Zhongshan, Shenzhen
2022-10-28
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Recruiting
Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
NCT05457049Non Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Active, closed
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613Breast Cancer
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Recruiting
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
NCT04778956Nasopharyngeal Carcinoma, PD-1, Surgery
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Recruiting
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
NCT06069232Aortic Valve Disease
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Recruiting
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
NCT04448522Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
NCT04085900Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
Observational
40,000
Zhongshan, Wuzhou
2020-04-01
Active, closed
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
NCT04384627Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
Sun Yat-sen University
Phase 3
445
Foshan, Zhongshan
2019-12-01
Recruiting
Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.
NCT04183829Reproductive Health, Abortion
National Research Institute for Family Planning, China
Observational
20,000
Zhongshan, Zhangjiakou, Daqing, Changzhou, Yangzhou, Hohhot, Qingdao, Zaozhuang
2019-06-01
Active, closed
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)
NCT03847857Esophageal Anastomotic Leak
Sun Yat-sen University
Phase 3
360
Guangzhou, Jieyang, Shantou, Zhongshan, Chengdu, Shanghai
2019-02-21
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Recruiting
Epstein-Barr Virus and Cancer Risks
NCT06203314Cancer
Sun Yat-sen University
Observational
100,000
Zhongshan, Wuzhou
2008-08-01
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhongshan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Zhongshan.

How many clinical trials are recruiting in Zhongshan?

38 of the 57 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 9 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhongshan), 57 studies
PhaseStudiesRecruitingShare
Phase 3191133.3%
Not applicable141124.6%
Observational121121.1%
Phase 26210.5%
Phase 1/2325.3%
Phase 4213.5%
Phase 2/3101.8%

Most active sponsors

Lead sponsors with the most studies (Zhongshan)
Lead sponsorStudiesRecruiting
Sun Yat-sen University1712
Zhongshan People's Hospital, Guangdong, China66
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University42
Ming-Yuan Chen33
Biogen20
Guangdong Provincial People's Hospital22
Nanfang Hospital, Southern Medical University21
AstraZeneca11
Beijing Tongren Hospital10
Bristol-Myers Squibb10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.